NCT06453395Completed
PPIO-009 Tumor Regression Grade and Tumor Location in Esophageal Cancer
PPIO-009 Tumor Regression Grade and Prognosis Analysis of Esophageal Cancer in Different Tumor Location After Neoadjuvant Immunotherapy
Source: ClinicalTrials.gov · Last updated 11 Jun 2024
Brief summary (registry, in English)
At present, the evaluation of the effect of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophageal cancer is mainly based on postoperative pathology, among which, the pathological assessment of tumor regression grade (TRG) and TNM staging are the basis for the routine pathological diagnosis of esophageal cancer, and the College of American Pathologists divides the TRG after neoadjuvant therapy to esophageal cancer into four grades: 0, 1, 2, and 3.The residual primary tumor in the resection specimen following neoadjuvant therapy is associated with shorter overall survival. Therefore ，the prediction of TRG after neoadjuvant therapy is vital for patients. We aim to seek to identify factors associated with TRG system as defined by the NCCN.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 248 (actual)
- First submitted
- 4 Jun 2024
- Start date
- 1 Jan 2023
- Primary completion date
- 4 Jun 2024
- Lead sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT06453395
What you commit to
- Study type: Observational
- Participants enrolled: 248
- From 1 Jan 2023 to the primary completion date, 4 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- 1\. nonradical resection (R1 or R2) 2. combined with other anticancer therapies (radiotherapy or Targeted drugs) 3. incomplete data or missing follow-up time 4. concurrent or previous presence of malignancies at other sites
Who the study is looking for
- 1\. Clinical diagnosis of Esophageal Squamous Cell Carcinoma 2. patients with clinical TNM (cTNM) stage II-IVA ESCC 3. patients with Neoadjuvant Immunochemotherapy before esophagectomy
Age in the registry: 18 years to 80 years · Sex: All
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Army Medical Center of the People's Liberation Army Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.